Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,023 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
Aribi A, Salhotra A, Afkhami M, Munteanu A, Ali H, Aldoss I, Otoukesh S, Al Malki MM, Sandhu KS, Koller P, Arslan S, Stewart F, Artz A, Curtin P, Ball B, O'Hearn J, Spielberger R, Smith E, Budde E, Nakamura R, Stein A, Forman S, Marcucci G, Becker PS, Pullarkat V. Aribi A, et al. Among authors: arslan s. Leuk Lymphoma. 2023 Nov-Dec;64(11):1811-1821. doi: 10.1080/10428194.2023.2241096. Epub 2023 Aug 3. Leuk Lymphoma. 2023. PMID: 37533373
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Aldoss I, et al. Among authors: arslan s. Blood Adv. 2019 Dec 10;3(23):4043-4049. doi: 10.1182/bloodadvances.2019000930. Blood Adv. 2019. PMID: 31816059 Free PMC article.
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E. Badar T, et al. Among authors: arslan s. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):556-560.e2. doi: 10.1016/j.clml.2020.03.004. Epub 2020 Mar 19. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32291234
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.
Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Badar T, et al. Among authors: arslan s. Blood Adv. 2020 May 26;4(10):2308-2316. doi: 10.1182/bloodadvances.2019001381. Blood Adv. 2020. PMID: 32453836 Free PMC article.
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Aldoss I, Zhang J, Mei M, Al Malki MM, Arslan S, Ngo D, Aribi A, Ali H, Sandhu K, Salhotra A, Koller P, Khaled S, Artz A, Snyder D, Nakamura R, Forman SJ, Stein AS, Marcucci G, Pullarkat V. Aldoss I, et al. Among authors: arslan s. Am J Hematol. 2020 Oct;95(10):1193-1199. doi: 10.1002/ajh.25929. Epub 2020 Jul 28. Am J Hematol. 2020. PMID: 32628327 Free article.
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E. Badar T, et al. Among authors: arslan s. Cancer. 2021 Apr 1;127(7):1039-1048. doi: 10.1002/cncr.33340. Epub 2020 Dec 1. Cancer. 2021. PMID: 33259056 Free article.
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Salhotra A, Aribi A, Ngo D, Zhang J, Sandhu K, Al-Malki M, Ali H, Koller P, Arslan S, Budde E, Khaled S, Dadwal S, Snyder DS, Artz A, Forman S, Nakamura R, Stein A, Marcucci G, Aldoss I, Pullarkat V. Salhotra A, et al. Among authors: arslan s. Am J Hematol. 2021 Jun 1;96(6):E196-E200. doi: 10.1002/ajh.26157. Epub 2021 Apr 8. Am J Hematol. 2021. PMID: 33719090 Free article. No abstract available.
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.
Aldoss I, Yang D, Malki MMA, Mei M, Mokhtari S, Artz A, Cao T, Salhotra A, Ali H, Aribi A, Khaled S, Arslan S, Sandhu K, Koller P, Mansour J, Spielberger R, Stein A, Snyder D, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Aldoss I, et al. Among authors: arslan s. Transplant Cell Ther. 2021 Mar;27(3):255.e1-255.e9. doi: 10.1016/j.jtct.2020.12.020. Epub 2020 Dec 22. Transplant Cell Ther. 2021. PMID: 33781525 Free article.
1,023 results